骨质减少:骨折预防的关键目标
本文综述了骨质减少(骨密度T值-1·0至-2·5)的骨折风险管理证据。超过60%的64岁以上白人女性存在骨质减少,尽管其骨折风险低于骨质疏松者,但因人数众多,多数骨折发生于骨质减少人群。骨折风险在骨质减少范围内差异很大,取决于骨密度、年龄、骨折史、国籍和种族等因素,因此骨质减少的诊断既不是干预指征也不是 reassurance 的依据,而应将骨密度纳入定量骨折风险计算。试验证据表明,口服和静脉双膦酸盐可经济有效地减少老年骨质减少女性的骨折。
要点
- 骨质减少定义为骨密度T值介于-1·0至-2·5,超过60%的64岁以上白人女性存在骨质减少。
- 多数骨折发生于骨质减少人群,但骨折风险在骨质减少范围内差异很大。
- 口服和静脉双膦酸盐可经济有效地减少老年骨质减少女性的骨折。
核心结论
- 骨质减少的诊断既不是干预指征也不是 reassurance 的依据,而应将骨密度纳入定量骨折风险计算。
- 口服和静脉双膦酸盐可经济有效地减少老年骨质减少女性的骨折。
- 对于65岁以上有治疗意愿的患者,主要骨质疏松性骨折风险达10-15%可能是使用仿制双膦酸盐可接受的指征。
研究设计与样本
- 本文为综述,评估了与老年骨质减少成人管理相关的证据。
主要发现
- 超过60%的64岁以上白人女性存在骨质减少。
- 尽管骨质减少女性的骨折风险通常低于骨质疏松女性,但其人数更多意味着多数骨折发生于骨质减少个体。
- 骨折风险在骨质减少范围内差异很大,取决于骨密度、年龄、骨折史、国籍和种族等因素。
- 试验证据表明,口服和静脉双膦酸盐可经济有效地减少老年骨质减少女性的骨折。
关键数值与推荐
- 骨质减少的定量定义为骨密度T值介于-1·0至-2·5。
- 主要骨质疏松性骨折风险达10-15%可能是65岁以上有治疗意愿患者使用仿制双膦酸盐可接受的指征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteopenia was originally a qualitative term denoting bone that appeared to be less dense on radiographs. Since 1994, it has also had the quantitative meaning of a bone mineral density (BMD) T-score between -1·0 and -2·5. More than 60% of White women older than 64 years are osteopenic. Although fracture risk is often lower in osteopenic women than in those with osteoporosis, their greater number means that most fractures occur in osteopenic individuals. Fracture risk varies widely in the osteopenic range, depending on factors including BMD, age, fracture history, and nationality and ethnicity. Therefore, the diagnosis of osteopenia is not an indication for either intervention or reassurance, but BMD is a risk factor that should be incorporated into a quantitative fracture risk calculation. Evidence from trials shows that oral and intravenous bisphosphonates cost-effectively reduce fractures in older osteopenic women. Major osteoporotic fracture risks of 10-15% could be acceptable indications for treatment with generic bisphosphonates in patients older than 65 years motivated to receive treatment. This Review assesses the evidence relating to the management of older adults with osteopenic bone densities.
引用
- Reid IR, McClung MR. Osteopenia: a key target for fracture prevention. Lancet Diabetes Endocrinol. 2024. PMID: 39326428. doi:10.1016/S2213-8587(24)00225-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。